<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210297</url>
  </required_header>
  <id_info>
    <org_study_id>LinMaxwell2018</org_study_id>
    <nct_id>NCT04210297</nct_id>
  </id_info>
  <brief_title>Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis</brief_title>
  <official_title>Development and Validation of an Noninvasive Model for Predicting High Risk Esophageal Varices in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Qilu Hospital of Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to develop and validate a new noninvasive method based on routine&#xD;
      examination during clinical practice for predicting high risk esophageal varices in&#xD;
      cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Portal hypertension is the main consequence of cirrhosis. Variceal bleeding is the principal&#xD;
      and life-threatening complication of portal hypertension. Endoscopic screening is the golden&#xD;
      standard to detect esophageal varices. However, endoscopy is limited by its invasiveness,&#xD;
      cost and the discomfort it imposes on patients. With the goal of circumventing these&#xD;
      disadvantages, we intend to develop an noninvasive method for predicting high risk esophageal&#xD;
      varices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">January 1, 2021</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>The golden standard is endoscopic examination.Compare the accuracy of the noninvasive model with the endoscopic examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>sensitivity</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>the sensitivity of predicting high risk esophageal varices of the noninvasive model.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>specificity</measure>
    <time_frame>through study completion, up to 2 years</time_frame>
    <description>the specificity of predicting high risk esophageal varices of the noninvasive model.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">245</enrollment>
  <condition>Esophageal and Gastric Varices</condition>
  <arm_group>
    <arm_group_label>Training cohort</arm_group_label>
    <description>Training cohort consists of the cirrhotic patients who collected from January 2018 to December 2019 of Qilu Hospital retrospectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Internal validation cohort</arm_group_label>
    <description>Internal validation cohort consists of the cirrhotic patients who enrolled from January 2020 of Qilu Hospital prospectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>External validation cohort</arm_group_label>
    <description>External validation cohort consists of the cirrhotic patients who enrolled from January 2020 in Jinan Central Hospital prospectively.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We queried the cirrhotic patients treated in Qilu Hospital Affiliated to Shandong&#xD;
        University and Jinan Central Hospital Affiliated to Shandong University.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The inclusion criteria:&#xD;
&#xD;
          1. patients who were diagnosed with liver cirrhosis.&#xD;
&#xD;
          2. patients who underwent the abdominal contrast-enhanced CT examination.&#xD;
&#xD;
          3. patients who received endoscopic screening.&#xD;
&#xD;
          4. patients with written informed consent.&#xD;
&#xD;
        The exclusion criteria:&#xD;
&#xD;
          1. patients who previously underwent endoscopic therapy, transjugular intrahepatic&#xD;
             portosystemic shunt (TIPS), splenectomy, partial splenic embolization (PSE),&#xD;
             hepatectomy, balloon-occluded retrograde transvenous obliteration, or liver&#xD;
             transplantation.&#xD;
&#xD;
          2. patients with liver cancer.&#xD;
&#xD;
          3. patients with severe ascites or hepatic encephalopathy.&#xD;
&#xD;
          4. lacks abdominal contrast-enhanced CT within 1 month of endoscopy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanjing Gao, PhD.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Gastroenterology,Qilu Hospital,Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 15, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Qilu Hospital of Shandong University</investigator_affiliation>
    <investigator_full_name>Yanjing Gao</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>noninvasive</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>radiomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

